WO2006078037A1 - チアゾリジンジオン化合物の製造方法及びその製造中間体 - Google Patents
チアゾリジンジオン化合物の製造方法及びその製造中間体 Download PDFInfo
- Publication number
- WO2006078037A1 WO2006078037A1 PCT/JP2006/301058 JP2006301058W WO2006078037A1 WO 2006078037 A1 WO2006078037 A1 WO 2006078037A1 JP 2006301058 W JP2006301058 W JP 2006301058W WO 2006078037 A1 WO2006078037 A1 WO 2006078037A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methoxy
- general formula
- methyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a high-purity thiazolidinedione compound having an excellent preventive and therapeutic action against diseases caused by insulin resistance, a crystal thereof, a production method and a production intermediate.
- Thiazolidinedione derivatives are diseases caused by insulin resistance such as diabetes, hyperglycemia, glucose intolerance, hypertension, hyperlipidemia, diabetic complications, gestational diabetes and polycystic ovary syndrome. It is known as a compound having an action of preventing and treating cardiovascular diseases such as sclerosis (see, for example, Patent Documents 1, 2, and 3).
- Patent Document 4 discloses the following production method (partial modification of the compound number in the formula of JP-A-2001-72671.
- R 1B is a C1-C6 alkyl group or C1-C6.
- An alkoxy group or the like R 2B represents a C1-C6 alkyl group
- R 3B represents a hydrogen atom or a protecting group).
- Patent Document 4 describes that a 1,2-phenol-diamine derivative represented by the general formula (2) and a compound (3) are subjected to a condensation reaction in the presence of a condensing agent. Specifically, the description of the production example of the compound represented by the general formula (4), in which R 1B is a methoxy group, R 2B force methyl group, and R 3B is a t-butoxycarbonyl group is described. A certain force reaction yield was 85%, and there was room for further improvement.
- Organochlorine solvents such as dichloromethane are widely used as solvents at the laboratory level because of their ease of use.
- dichloromethane is widely used as solvents at the laboratory level because of their ease of use.
- there is a suspicion of toxicity and the like there is a need for a synthetic method without using dichloromethane in an industrial process that uses a large amount of a solvent.
- Patent Document 1 Japanese Patent Laid-Open No. 9-95970
- Patent Document 2 JP 2001-39976 A
- Patent Document 3 International Publication No. 00/71540 Pamphlet
- Patent Document 4 JP 2001-72671 A
- Non-Patent Document 1 Journal ⁇ Ob ⁇ Chemical Society 'Perkin.Transaction • I [J. Chem. Soc. Perkin I] (UK) 1992, p.973-978
- Non-Patent Document 2 Bioorganic and 'Medicine' Chemistry 'Letters [Bioorg anic Med. Chem. Lett.] (UK) 14th, .235-238 (2004)
- Substances used for pharmaceuticals are required to have particularly high purity so as to prevent unexpected side effects (for example, toxicity and the like) due to impurities. Furthermore, in the industrial production method (mass production method), it is required to remove impurities by a simpler operation.
- the present inventors have found that diseases caused by insulin resistance (preferably diabetes, hyperglycemia, glucose intolerance, hypertension, hyperlipidemia, diabetic complications, gestational diabetes, Cyst egg A thiazolidinedione-inducible conductor, which has an excellent preventive and therapeutic action for nest syndrome, more preferably diabetes, hyperglycemia, glucose intolerance, particularly preferably diabetes.
- diseases caused by insulin resistance preferably diabetes, hyperglycemia, glucose intolerance, hypertension, hyperlipidemia, diabetic complications, gestational diabetes, Cyst egg A thiazolidinedione-inducible conductor, which has an excellent preventive and therapeutic action for nest syndrome, more preferably diabetes, hyperglycemia, glucose intolerance, particularly preferably diabetes.
- the present invention provides:
- interplanar spacing d 14.29, 7.12, 5.34, 4.97, 4.74, 3.95, 3.85, 3. 75, 3.55, 3.51, 3.15, 2.84, 2.76
- interplanar spacing d 14.29, 7.12, 5.34, 4.97, 4.74, 3.95, 3.85, 3. 75, 3.55, 3.51, 3.15, 2.84, 2.76, 2.52, and 2.37.
- interplanar spacing d 14.29, 7.12, 5.34, 4.97, 4.74, 3.95, 3.85, 3. 75, 3.55, 3.51, 3.15, 2.84, 2.76, 2, 52, and 2.37.
- R 4 is the same or different and represents a hydrogen atom, a hydroxyl group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a benzyloxy group, an acetoxy group, a trifluoromethyl group, or a halogen atom
- R 5 is a CI-C6 Indicates an alkyl group. Or a pharmaceutically acceptable salt thereof,
- X is a chlorine atom
- X represents a halogen atom.
- R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom, a hydroxyl group, a CI—C6 alkyl group, a CI—C6 alkoxy group, a benzyloxy group, an acetoxy group, or a trifluoro group.
- a methyl group or a halogen atom R 5 represents a CI—C6 alkyl group
- R 6 represents a protecting group for an amino group.
- R IT and IT are the same or different and each represents a hydrogen atom, a hydroxyl group, a C1-C6 alkyl group, a CI-C6 alkoxy group, a benzyloxy group, an acetoxy group, a trifluoromethyl group or a halogen.
- R 5 represents a CI—C6 alkyl group
- R 6 represents a protecting group for an amino group.
- the organic solvent of the crude crystal of the compound represented by the above formula (wherein the organic solvent is selected from alcohols, ethers, nitriles or a mixed solvent thereof) is refluxed. Purification method,
- the compound represented by the general formula (III) is N— ⁇ 2— ⁇ 4 [(2,4 Dioxothiazolidine 5 —yl) methyl] phenoxycetylamino ⁇ — 5 -methoxyphenyl ⁇ —
- R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom, a hydroxyl group, a CI—C6 alkyl group, a CI—C6 alkoxy group, a benzyloxy group, an acetoxy group, or a trifluoro group.
- a methyl group or a halogen atom R 5 represents a CI—C6 alkyl group
- R 6 represents a protecting group for an amino group.
- the organic compound (the organic solvent is selected from alcohols, ethers, nitriles or a mixed solvent thereof) suspension or solution of the compound represented by the following formula:
- the following general formula (A) is characterized in that the amount of impurities in the final product is 2% or less.
- R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom, a hydroxyl group, a CI—C6 alkyl group, a CI—C6 alkoxy group, a benzyloxy group, an acetoxy group, a trifluoro group; A methyl group or a halogen atom; R 5 represents a CI—C6 alkyl group; and R 6 represents a protecting group for an amino group.
- the following general formula (III) obtained by reacting with a compound represented by formula (III)
- R 2 , R 3 and R 4 are as defined above.
- X represents a halogen atom.
- a salt thereof is represented by the following general formula (II) [0042]
- R 5 and R 6 are the same or different and each represents a hydrogen atom, a hydroxyl group, a CI—C6 alkyl group, a CI—C6 alkoxy group, a benzyloxy group, an acetoxy group, a trifluoromethyl group, or a halogen atom
- R 5 is a CI—C6 Represents an alkyl group
- R 6 represents a protecting group for an amino group.
- R 4 has the same meaning as described above.
- the thiazolidinedione compound represented by the general formula (A) is ⁇ 5—4 -— [(6-methoxy-1-methyl-1-H-benzimidazole-2-yl) methoxy] benzyl ⁇
- R 2 , R 3 and R 4 are the same or different and each represents a hydrogen atom, a hydroxyl group, a CI—C6 alkyl group, a CI—C6 alkoxy group, a benzyloxy group, an acetoxy group, or a trifluoro group.
- a methyl group or a halogen atom R 5 represents a CI—C6 alkyl group
- R 6 represents a protecting group for an amino group.
- a pharmaceutical composition comprising the crystals described in the above (1) to (3) as an active ingredient, (24)
- diabetes hyperglycemia, glucose intolerance, hypertension, hyperlipidemia, diabetic complications, gestational diabetes mellitus, polycystic ovary symptom group containing crystals described in (1) to (3) as an active ingredient or A pharmaceutical composition for preventing or treating atherosclerosis, (25)
- a pharmaceutical composition for preventing or treating diabetes comprising the crystals described in (1) to (3) as an active ingredient,
- a pharmaceutical composition comprising the compound according to (4) to (6) above or a pharmacologically acceptable salt thereof,
- a pharmaceutical composition for the prevention or treatment of ovarian ovary syndrome or atherosclerosis A pharmaceutical composition for the prevention or treatment of ovarian ovary syndrome or atherosclerosis,
- a pharmaceutical composition for the prevention or treatment of diabetes comprising the compound according to (4) to (6) above or a pharmacologically acceptable salt thereof,
- a pharmaceutical composition comprising the compound according to (21) or (22) or a pharmacologically acceptable salt thereof,
- Corrected form (Rule 91) Glycouria, hyperglycemia, glucose intolerance, hypertension, hyperlipidemia, diabetic complications, gestational diabetes, containing the compound according to (21) or (22) above or a pharmacologically acceptable salt thereof, A pharmaceutical composition for the prevention or treatment of polycystic ovary syndrome or atherosclerosis,
- a pharmaceutical composition for preventing or treating glycouric disease comprising the compound according to (21) or (22) or a pharmacologically acceptable salt thereof,
- a method for preventing or treating diabetes comprising administering the crystal described in (1) to (3) above,
- a method for preventing or treating diabetes comprising administering the compound according to (4) to (6) or a pharmacologically acceptable salt thereof,
- a method for preventing or treating diabetes comprising administering the compound according to (21) or (22) or a pharmacologically acceptable salt thereof,
- ⁇ 5— 4— [(6-Methoxy-1- 1-methyl-1-H-benzimidazole-2-yl) methoxy] benzyl ⁇ thiazolidine 1,2,4-dione Hydrochloride content is 99% by weight excluding water Surface spacing d 14.29, 7.12, 5.34, 4.97, 4.74, 3.95, 3. 85, 3.75, 3.55, 3.51, 3.15, 2.84, 2.76, 2.52 and 2.37 are characterized by the main peaks, ⁇ 5-4— [ (6-Methoxy-1-methyl-1-H-benzimidazole-2-yl) methoxy] benzyl ⁇ thiazolidine-1,4-dione hydrochloride crystal composition,
- ⁇ 5— 4 _ [(6-Methoxy-1- 1-methyl-1-H-benzimidazole-2-1-f-nore) methoxy] benzyl ⁇ thiazolidine-1-2,4-dione
- the content of hydrochloride, excluding water, is 99 Composition of purified ⁇ 5—4-[[(6-Methoxy-1-methinoleol 1H-benzimidazole-1-2-yl) methoxy] benzyl ⁇ thiazolidine mono-2,4-dione hydrochloride that is greater than wt% Is a thing
- purity is a value measured by quantitative analysis.
- CI-C6 alkyl group is a linear or branched alkyl group having 1 to 6 carbon atoms, such as methyl, ethinole, propyl, isopropinole, butinole, isobuta
- R 4 and R 5 are preferably CI—C 4 alkyl groups, more preferably ethyl or methyl groups, and particularly preferably methyl groups.
- the “C1-C6 alkoxy group” is a group in which the C1 C6 alkyl group is bonded to an oxygen atom.
- R 2 , R 3 and R 4 are preferably CI C4 alkoxy groups, more preferably ethoxy or methoxy groups, and particularly preferably methoxy groups.
- halogen atom is a fluorine, chlorine, bromine, or iodine atom.
- R 4 and X are preferably fluorine, chlorine, or bromine atoms, and more preferably chlorine.
- the “amino group protecting group” is not particularly limited as long as it is usually used as an amino group protecting group.
- trityl, monomethoxytrityl, dimethoxytrityl, Substituted with C1-C6 alkyl, C1-C6 alkoxy or halogen such as trimethoxytrityl, benzyl, methylbenzyl, methoxybenzyl, black benzyl, bromobenzyl or naphthylmethyl groups, but may also be an arylmethyl group
- C1 C6 alkyl, CI-C6 alkoxy or halogen such as benzyloxycarbonyl, methylbenzyloxycarbonyl, methoxybenzyloxycarbonyl, chlorobenzyloxycarbonyl, bromobenzyloxycarbonyl or naphthylmethylcarbonyl Hey, hey Chiruokishikarubo - group, ⁇ Lil O
- R 6 preferably t-butoxycarbol, benzyl, p-methoxybenzyl, p-bromobenzyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-bromobenzyloxycarbol or And, more preferably, t-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-bromobenzyloxycarbo- yl or aryloxycarbo- yl.
- -Tyl group, and t-butoxycarbol group is particularly preferable.
- R 1 is preferably a hydrogen atom or a C1-C4 alkoxy group, more preferably a hydrogen atom or a methoxy group, and particularly preferably a hydrogen atom.
- R 2 is preferably a hydrogen atom or a C1-C4 alkoxy group, more preferably a hydrogen atom or a methoxy group, and particularly preferably a hydrogen atom.
- R 3 is preferably a hydrogen atom or a C1-C4 alkoxy group, more preferably a hydrogen atom or a methoxy group, and particularly preferably a methoxy group.
- R 4 is preferably a hydrogen atom or a C1-C4 alkoxy group, more preferably a hydrogen atom or a methoxy group, and particularly preferably a hydrogen atom.
- R 5 is preferably a CI-C4 alkyl group, more preferably a CI-C2 alkyl group, and particularly preferably a methyl group.
- R 6 is preferably a t-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarboxyl or p-bromobenzyloxycarbo ol group, and more preferably Is a t_butoxycarbole.
- X is preferably a chlorine atom.
- the method of the present invention produces an acid halide compound represented by the compound (I) by reacting 4 [(2,4 dioxothiazolidine 5-yl) methyl] phenoxyacetic acid with a halogenating agent.
- This process is a process for producing acid halides (I).
- 4-[(2,4-Dioxothiazolidine 5-yl) methyl] phenoxyacetic acid is reacted with a halogenating agent. It is achieved by the fact that it is made to do.
- the halogenating agent used in this step is not particularly limited as long as it can convert a carboxylic acid into an acid halide.
- a halogenating agent include thionyl chloride, thionyl bromide, salt oxalyl, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride, etc., preferably salt thiol, Examples thereof include chlorooxalyl and phosphorus pentachloride, with thionyl chloride being particularly preferred.
- the amount of the halogenating agent used in this step is not particularly limited as long as it is 1 equivalent or more with respect to the 4-[(2,4 dioxothiazolidine-l-yl) methyl] phenoxyacetic acid used. , Preferably 1 to 2 equivalents, more preferably 1 to 1.2 equivalents.
- the reaction is usually carried out in a solvent. When a solvent is used, there is no particular limitation as long as it does not inhibit the reaction.
- Such solvents include, for example, hexane, heptane, lignin, or aliphatic hydrocarbons such as petroleum ether, aromatic hydrocarbons such as benzene, toluene, xylene, acetonitrile, propio-tolyl.
- -Tolyls such as benzo-tolyl, dichloromethane, chloroform, 1,2-dichloroethane, halogenated hydrocarbons such as carbon tetrachloride, jetyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane , Ethers such as diethylene glycol dimethyl ether, formamide, dimethylformamide, dimethylacetamide, amides such as hexamethylphosphoric triamide, sulfoxides such as dimethyl sulfoxide, sulfolane, and mixtures thereof, preferably Is halogen ⁇ Hydrocarbons, nitriles, ethers or amides, and mixtures thereof, more preferably acetonitrile, dichloromethane, chloroform, tetrahydrofuran, dimethylformamide or mixtures thereof, particularly preferred Is dichloromethane or acetonitrile.
- the reaction may proceed more rapidly by adding a catalyst.
- a catalyst When a catalyst is added, usually a amine, a derivative of amine, or a nitrogen-containing heterocyclic compound is used as the catalyst.
- a tertiary amine When an amine is used, a tertiary amine is usually used.
- examples of such amines include trialkylamines such as trimethylamine, triethylamine, diisopropylethylamine or tributylamine, ⁇ , ⁇ -dimethylaniline, Examples thereof include dialkylarylamines such as ⁇ and ⁇ -jetaline, and diarylalkylamines such as diphenylmethylamine.
- Derivatives of amines include ⁇ , ⁇ -dialkylamides such as dimethylformamide or dimethylacetamide.
- nitrogen-containing heterocyclic compound examples include pyridine, ⁇ , ⁇ -dimethyl-4-aminoviridine, imidazole, and triazole.
- Preferred are trimethylamine, triethylamine, diisopropylethylamine, tributylamine, ⁇ , ⁇ -dimethylaniline, dimethylformamide or dimethylacetamide, pyridine, ⁇ , ⁇ -dimethyl-4-aminoviridine, and more preferred.
- the amount of the catalyst used is not particularly limited, but is usually 0.01 to 20 with respect to the halogenating agent used. Equivalent, preferably 0.1 to 10 equivalents, more preferably 0.3 to 5 equivalents.
- the reaction temperature in this step varies depending on the raw material compounds, reagents and the like, but is usually ⁇ 20 ° C. to 150 ° C., preferably ⁇ 10 ° C. to 100 ° C., more preferably ⁇ 10 to 40 ° C.
- reaction time of this step varies depending on the raw material compounds, reagents, reaction temperature, etc., but is usually 30 minutes force 80 hours, preferably 30 minutes force 48 hours, more preferably 1 hour. Power is 6 hours.
- compound (I) or a salt thereof may be isolated and then the second step may be performed, or the second step may be performed without isolation. It is better to carry out the second step without releasing.
- This step is a step for producing the compound (III), and is achieved by reacting the acid halide (I) with the known ferrodiamine compound (II) in an inert solvent.
- the reaction when a base is used, the reaction may proceed rapidly.
- examples of the base used include alkali metal carbonates such as lithium carbonate, sodium carbonate, and potassium carbonate, alkali metal heavy metals such as lithium hydrogen carbonate, sodium hydrogen carbonate, and hydrogen hydrogen carbonate.
- Alkali metal hydrides such as carbonates, lithium hydride, sodium hydride, hydrogen hydride, lithium hydroxide, sodium hydroxide, alkali metal hydroxides such as lithium hydroxide, lithium methoxy Alkali metal alkoxides such as sodium methoxide, sodium methoxide, potassium t-butoxide, triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- ( ⁇ , ⁇ -dimethylamino) Pyridine, ⁇ , ⁇ -dimethylaline, ⁇ , ⁇ -jetylaline, 1 , 5-Diazabicyclo [4.3.0] Nano-5-ene, 1,4-Diazabicyclo [2.2.2] Octane (DABCO), 1,8-Diazabicyclo [5.4.0] -7-undecene (DBU)
- Organic amines preferably organic amines, more preferably triethylamine, tributy
- This step is usually performed in a solvent.
- the solvent is not particularly limited as long as it does not inhibit the reaction.
- Such solvents include, for example, hexane, heptane, lignin, or aliphatic hydrocarbons such as petroleum ether, aromatics such as benzene, toluene, xylene.
- Aromatic hydrocarbons, acetonitrile, propio-tolyl, -tolyl such as benzo-tolyl, halogenated hydrocarbons such as dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride, jetyl ether , Ethers such as diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, diethylene glycol dimethyl ether, amides such as formamide, dimethylformamide, dimethylacetamide, hexamethylphosphoric triamide, sulfoxides such as dimethyl sulfoxide, sulfolane , And mixtures thereof, preferably halogenated hydrocarbons, nitriles, ethers or amides, and mixtures thereof, more preferably acetonitrile, dichloromethane, chloride, and the like. mouth Form, tetrahydrofuran, dimethylformamide or a
- the reaction temperature in this step varies depending on the raw material compounds, reagents and the like, but is usually -20 ° C to 150 ° C, preferably -20 ° C to 100 ° C.
- the reaction time in this step varies depending on the raw material compounds, reagents, reaction temperature, etc., but is usually from 30 minutes to 80 hours. It is preferably 1 to 48 hours.
- the compound (III) is isolated by an isolation operation such as natural crystallization or extraction and concentration after usual post-treatment, and then the third step or the fourth step. carry out.
- compound (III) is heated and stirred in an organic solvent, dissolved or suspended, and then cooled to remove impurities by recrystallization or resuspension to produce compound (III) with higher purity.
- this step can be omitted if the compound (III) is not crystalline or if the purity is sufficiently high.
- This step is performed in a solvent.
- the solvent is not particularly limited as long as it does not react with compound (III) and dissolves to some extent.
- solvents include alcohols such as methanol, ethanol, propanol, isopropyl alcohol, and butyl alcohol, -tolyls such as acetonitrile, propio-tolyl, and benzo-tolyl, jetyl ether, diisopropyl ether, Ethers such as tetrahydrofuran, dioxane, dimethoxyethane, and ethylene glycol dimethyl ether, and mixtures thereof.
- Acetonitrile, methanol, ethanol, or a mixture thereof is preferable, and methanol is particularly preferable.
- the heating temperature in this step varies depending on the properties of compound (III) and the solvent. Usually, it is room temperature to the reflux temperature of the solvent used, and preferably the reflux temperature of the solvent used.
- the time of this step varies depending on the properties of compound (III) and the solvent. Usually, it is 10 minutes to 20 hours, preferably 20 minutes to 10 hours.
- This step is a step for producing the final target compound (A) and can be achieved by cyclizing the compound (III) in the presence of an acid.
- This step is performed in a solvent.
- the solvent is not particularly limited as long as it does not react with compound (III) and dissolves to some extent.
- solvents include, for example, hexane, heptane, lignin, or aliphatic hydrocarbons such as petroleum ether, aromatic hydrocarbons such as benzene, toluene, xylene, methanol, ethanol, Alcohols such as propanol, isopropyl alcohol, butyl alcohol, acetonitrile, propiotolyl, -tolyls such as benzo-tolyl, dichloromethane, chloroform, 1,2-dichloroethane, tetrasalt carbon Halogenated hydrocarbons, ethers such as jetyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, diethylene glycol dimethyl ether, and mixtures thereof, preferably halogenated hydrocarbon
- Bronsted acid or Lewis acid deviation is used, but usually Bronsted acid is used.
- the Bronsted acid usually used in this step is not particularly limited, but examples thereof include inorganic acids such as hydrogen chloride, hydrogen bromide, hydrochloric acid, bromic acid, sulfuric acid, nitric acid, phosphoric acid and boric acid, formic acid, acetic acid and propionic acid.
- Organic acids such as oxalic acid, succinic acid, maleic acid, hydroxyacetic acid, fumaric acid, succinic acid, tartaric acid, benzoic acid and salicylic acid.
- hydrochloric acid, sulfuric acid, acetic acid, citrate, and tartaric acid more preferably hydrochloric acid and sulfuric acid, and particularly preferably hydrochloric acid.
- the acid of the salt to be produced can be used as it is to obtain the corresponding salt.
- the amount of the acid used in this step is not particularly limited as long as it is 1 equivalent or more with respect to the compound (III) to be used, but is preferably 1 to 15 equivalents, more preferably 2 to 8 equivalents.
- the reaction temperature in this step varies depending on the properties of the compound (III), acid and solvent. Usually, the temperature is from room temperature to 100 ° C, preferably from 35 ° C to 80 ° C, more preferably 40 ° C to 60 ° C.
- reaction time in this step varies depending on the properties of the compound (111), acid and solvent, it is generally 30 min to 20 hr, preferably 1 hr to 10 hr.
- the compound (A) or a salt thereof crystallizes as crystals after completion of the reaction in this step, it can be isolated by a filtration operation.
- compound (A) or a salt thereof does not become a crystal, it can be isolated by an isolation operation such as an extraction operation after usual post-treatment.
- the obtained compound (A) may be used as it is after drying, or may be used after carrying out usual purification operations such as recrystallization and column chromatography.
- the pharmaceutical containing the high-purity thiazolidinedione compound of the present invention and crystals thereof can be used in preparations that can be administered orally, such as tablets, capsules, pills, granules, or fine granules. Preferably, it is a tablet.
- the above-mentioned preparation may appropriately contain a pharmaceutically acceptable additive.
- additives include, for example, excipients (eg, sugar derivatives such as lactose, sucrose, glucose, mannitol, sorbitol; corn starch, potato starch, pregelatinized starch, dextrin, carboxymethyl starch, Starch derivatives such as sodium carboxymethyl starch; pregelatinized starch; crystalline cellulose, methylcellulose, hydroxypropylcellulose, low substituted hydroxypropylcellulose, hydroxypropylmethy Cellulose derivatives such as Noresenorelose, Canolemellose, Canolemellose Canolecium, Croscanolemellose, Cross-Force Noremelose Sodium; gum arabic; dextran; pullulan; light anhydrous carboxylic acid, calcium silicate, silicic acid hydrate Synthetic aluminum silicate, metasilicate, silicate derivatives such as magnesium aluminate; phosphate derivative
- the content of the binder is generally 1 to 10 parts by weight (preferably 2 to 5 parts by weight) in the total drug composition, and the content of the disintegrant is Usually, it is 1 to 40 parts by weight (preferably 5 to 30 parts by weight), and the content of the lubricant is usually 0.1 to 10 parts by weight (preferably 0.5 to 3 parts by weight).
- the content of the fluidizing agent is 0.1 to 10 parts by weight (preferably 0.5 to 5 parts by weight).
- composition of the present invention is prepared by a well-known method (for example, using a pharmaceutically acceptable additive)
- Kneading method using water, wet granulation method, etc. examples include, for example, the addition of active ingredients, stabilizers, excipients, binders, disintegrants and other types of auxiliaries as necessary, and mixing with a high-speed stirring granulator. Then, an aqueous solution of a binder is added to the obtained mixture and kneaded to obtain a granulated product. The obtained granulated product is dried using a fluidized bed dryer, and the dried granulated product is forcibly passed through a screen using a crushing and granulating granulator to obtain a lubricant and a disintegrant. If necessary, add other types of auxiliaries and mix with a V-type mixer, and the resulting mixture is compressed into tablets or capsules to produce tablets or capsules, respectively. be able to.
- the obtained tablets can be sugar-coated or coated (preferably, coated) as necessary.
- the resulting tablet is sprayed with a coating solution of hydroxypropylmethylcellulose, tar, titanium oxide, lactose, triacetin or polyethylene glycol, yellow iron sesquioxide or iron sesquioxide, and hydraulic power in a pan coating machine. By doing so, a film coating can be applied.
- the kneaded product obtained by mixing with the high-speed agitation granulator and adding the aqueous solution of the binder to knead is formed into granules using an extrusion granulator, and then fenced.
- a granule can be produced by forcibly passing the dried granule through a screen using a crushing and granulating granulator.
- the pharmaceutical thread composition of the present invention can be administered to warm-blooded animals (particularly humans) and is an active ingredient 5- [4- (6-methoxy-1-methyl-1H-benzimidazole].
- -2-ylmethoxy) benzyl] thiazolidine-2,4-dione or a pharmacologically acceptable salt thereof depends on the patient's symptoms, age, although it may vary depending on various conditions such as body weight, for example, in the case of oral administration, O.lmg / body to 20mg / body (preferably 0.5mg / body to 3mg / body) per person is Can be administered 1 to 6 times daily depending on symptoms.
- the present invention provides crystals of thiazolidinedione derivatives having an excellent preventive and therapeutic action for diseases caused by known insulin resistance, and a production method suitable for mass synthesis thereof.
- a target compound having a high yield, high purity, an inexpensive reagent and a simple operation with a small environmental load even when mass synthesis is performed.
- acetonitrile 240 ml was added dropwise over 65 minutes while cooling so that the reaction temperature was maintained at 0 to 5 ° C., and the mixture was further stirred at the same temperature for 2 hours.
- water 320 ml was added over 15 minutes, and the mixture was stirred at an internal temperature of 0 to 5 ° C. for 2.5 hours, and then the precipitated crystals were separated by filtration.
- N- (2 amino-5-methoxyphenol) N-methylcarbamate tert-butyl (38.4 g, 137.9 mmol) and triethylamine (18.7 g, 184.9 mmol) acetonitrile (240 ml) held at 0-10 ° C.
- the solution was added dropwise over 65 minutes while cooling so that the reaction temperature was maintained at 0 to 3 ° C., and the mixture was further stirred at the same temperature for 3.5 hours.
- water (320 ml) was added over 27 minutes, and the mixture was stirred at 0 to 5 ° C. for 2.5 hours.
- Methanol (305 L) was poured into this, and the mixture was concentrated to about 300 under reduced pressure at an internal temperature of 20-30 ° C. Further, methanol (305) was poured here, and the paper was darkly corrected until it reached about 300 under a reduced pressure at an internal temperature of 20-30 ° C (Rule 91). Shrinked. Methanol (201L) was poured into this and stirred at 5 ° C for 1 hour.
- N— ⁇ 2— ⁇ 4— [(2,4-Dioxothiazolidine-5-yl) methyl] phenoxycetylamino ⁇ -5-methoxyfuel) obtained from (5-1) 5 hours after suspending tert-butyl N-methylolenolevamate (97.0 kg, 188.1 mol) in a solution of methanol (2803 L), water (43 L) and 38% hydrochloric acid (72.8 kg) Refluxed with stirring. The reaction solution was cooled to 0-5 ° C, stirred for 1 hour, and allowed to stand at the same temperature for 12 hours.
- tert-butyl N- (2-amino-1-methoxymethoxy) -N-methylcanolebamate (15.7 kg, 62.2 mol) and triethylamine (8.4 kg, 83.0) kept at 0 to 10 ° C. mol) of acetonitrile (84.6 kg) was added dropwise over 1 hour while cooling so that the reaction temperature was maintained at 0 to 5 ° C., and the mixture was further stirred at the same temperature for 2 hours.
- water (144 L) was added over 22 minutes, and the mixture was stirred for 30 minutes while maintaining the internal temperature of 0 to 6 ° C, and then allowed to stand for 12 hours.
- N— ⁇ 2- ⁇ 4- [(2,4-Dioxothiazolidine mono-5-yl) methinole] phenoxyacetylamino ⁇ obtained from (6-1) 1- 5-methoxyphenyl ⁇ -
- the suspension was refluxed in methanol (450 L) of wet crystals of tert-butyl N-methylcarnomate for 25 minutes with stirring.
- the suspension was cooled to 0-5 ° C and stirred at the same temperature for 1 hour, and the precipitated crystals were filtered off.
- the crystals obtained in Example 3, the crystals obtained in Example 3 stored at 40 ° C. for 40 days, the purified crystals obtained in Example 4 and the purified crystals obtained in Example 4 were obtained.
- the quality of four samples of crystals stored for 42 days at ° C was analyzed.
- the quality analysis method is as follows.
- each test substance has a difference in production method as described in the above examples.
- the crystals of Example 4 Is produced by a synthesis method according to the scheme.
- the crystal of Example 3 was produced without purification in the third step in the following scheme.
- Test substance 1 Compound of Example 5
- Test substance 2 Compound of Example 6
- HPLC conditions are as follows.
- Compound (A 1 ) content (%) WXFX (Q / Q) X [1 / ⁇ WX (100-F) / 100 ⁇ ] X
- Each test substance has a difference in production method as described in the above examples.
- the following The crystal of Example 6 was produced by a synthesis method according to the scheme.
- the crystal of Example 5 was purified without performing the purification in the third step in the following scheme.
- the method described in International Publication No. 00/71540 is a route that does not use the intermediate acid halide (I), and is manufactured by a method that does not require purification in the third step. .
- Table 3 shows that a significant reduction in the amount of impurities was observed by adding the third step of purification, indicating that this purification method is particularly excellent in removing impurities.
- tablets were obtained by the following method. Note that the dose of active ingredient, the content and type of each additive are not limited to those in Table 5.
- Example 5 To the crystals of Example 5, an excipient (Lactose) and a disintegrant (croscarmellose sodium (Ac-D ⁇ Sol)) were added and mixed with a high-speed stirring granulator to obtain A binder (hydroxypropylcellulose) aqueous solution was added to the mixture and kneaded to obtain a granulated product, which was dried using a fluid bed dryer, and the dried granulated product was crushed. The screen was forcibly passed using a granulator, and a lubricant (magnesium stearate) was added and mixed with a V-type mixer. An aqueous coating (OPADRY WHITE YS-1-18202A) solution in which a pigment (yellow ferric oxide) was dispersed was sprayed using a coating machine to obtain a desired tablet.
- an excipient Licose
- croscarmellose sodium (Ac-D ⁇ Sol) croscarmellose sodium (Ac-
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06712274A EP1894929A4 (en) | 2005-01-24 | 2006-01-24 | METHOD FOR PRODUCING A THIAZOLIDINEDION COMPOUND AND INTERMEDIATE PRODUCT THEREOF |
CA2595782A CA2595782C (en) | 2005-01-24 | 2006-01-24 | Process for producing thiazolidinedione compound and production intermediate thereof |
BRPI0606931-2A BRPI0606931A2 (pt) | 2005-01-24 | 2006-01-24 | composto, processos para a produção de um composto, e para a purificação de um composto, composição, e, usos do cristal, e do composto |
IL184598A IL184598A0 (en) | 2005-01-24 | 2007-07-12 | A crystal of a thiazolidinedione derivative and processes for the preparation tereof |
US12/928,525 US20110092555A1 (en) | 2005-01-24 | 2010-12-14 | Thiazolidinedione compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-014930 | 2005-01-24 | ||
JP2005014930 | 2005-01-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/928,525 Division US20110092555A1 (en) | 2005-01-24 | 2010-12-14 | Thiazolidinedione compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006078037A1 true WO2006078037A1 (ja) | 2006-07-27 |
Family
ID=36692408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/301058 WO2006078037A1 (ja) | 2005-01-24 | 2006-01-24 | チアゾリジンジオン化合物の製造方法及びその製造中間体 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20080103185A1 (ja) |
EP (2) | EP2226321A3 (ja) |
KR (1) | KR20070098872A (ja) |
CN (1) | CN101146805A (ja) |
BR (1) | BRPI0606931A2 (ja) |
CA (2) | CA2699633A1 (ja) |
IL (1) | IL184598A0 (ja) |
TW (1) | TW200637856A (ja) |
WO (1) | WO2006078037A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10064850B2 (en) | 2007-04-11 | 2018-09-04 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007007656A1 (ja) * | 2005-07-08 | 2007-01-18 | Daiichi Sankyo Company, Limited | チアゾリジンジオン化合物を含有する医薬組成物 |
CN102725288A (zh) | 2009-11-26 | 2012-10-10 | 第一三共株式会社 | 用于制造6-取代的1-甲基-1h-苯并咪唑衍生物的方法和所述方法的中间体 |
CN101973957B (zh) * | 2010-05-27 | 2012-11-21 | 四川大学 | 5-苯亚甲基-2,4-噻唑烷二酮衍生物及其制备方法和用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0995970A (ja) | 1995-09-29 | 1997-04-08 | Nitto Seiko Co Ltd | 泥水分離装置 |
JPH09295970A (ja) * | 1995-06-01 | 1997-11-18 | Sankyo Co Ltd | 縮合複素環化合物 |
WO2000071540A1 (fr) | 1999-05-24 | 2000-11-30 | Sankyo Company, Limited | Chlorhydrate de compose heterocyclique fusionne |
WO2001000570A1 (fr) * | 1999-06-28 | 2001-01-04 | Sankyo Company, Limited | Intermediaires pour la synthese de composes de benzimidazole et procede de preparation |
JP2001039976A (ja) | 1999-05-24 | 2001-02-13 | Sankyo Co Ltd | 縮合複素環化合物の塩酸塩 |
JP2001072671A (ja) | 1999-06-28 | 2001-03-21 | Sankyo Co Ltd | ベンズイミダゾール化合物の合成中間体およびその製造方法 |
JP2001097954A (ja) * | 1999-07-29 | 2001-04-10 | Sankyo Co Ltd | スルホキシベンズイミダゾール誘導体 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985884A (en) * | 1996-07-01 | 1999-11-16 | Dr. Reddy's Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
IL145732A0 (en) * | 1999-04-06 | 2002-07-25 | Sankyo Co | α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
EP1798216A4 (en) * | 2004-09-28 | 2008-12-03 | Sankyo Co | INTERMEDIATE PRODUCT OF A 6-SUBSTITUTED 1-METHYL-1H-BENZIMIDAZOLE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF |
-
2006
- 2006-01-23 TW TW095102456A patent/TW200637856A/zh unknown
- 2006-01-24 US US11/795,270 patent/US20080103185A1/en not_active Abandoned
- 2006-01-24 KR KR1020077016748A patent/KR20070098872A/ko not_active Application Discontinuation
- 2006-01-24 CA CA2699633A patent/CA2699633A1/en not_active Abandoned
- 2006-01-24 CN CNA2006800094040A patent/CN101146805A/zh active Pending
- 2006-01-24 CA CA2595782A patent/CA2595782C/en not_active Expired - Fee Related
- 2006-01-24 EP EP10006276A patent/EP2226321A3/en not_active Withdrawn
- 2006-01-24 EP EP06712274A patent/EP1894929A4/en not_active Withdrawn
- 2006-01-24 WO PCT/JP2006/301058 patent/WO2006078037A1/ja active Application Filing
- 2006-01-24 BR BRPI0606931-2A patent/BRPI0606931A2/pt not_active IP Right Cessation
-
2007
- 2007-07-12 IL IL184598A patent/IL184598A0/en unknown
-
2010
- 2010-12-14 US US12/928,525 patent/US20110092555A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09295970A (ja) * | 1995-06-01 | 1997-11-18 | Sankyo Co Ltd | 縮合複素環化合物 |
JPH0995970A (ja) | 1995-09-29 | 1997-04-08 | Nitto Seiko Co Ltd | 泥水分離装置 |
WO2000071540A1 (fr) | 1999-05-24 | 2000-11-30 | Sankyo Company, Limited | Chlorhydrate de compose heterocyclique fusionne |
JP2001039976A (ja) | 1999-05-24 | 2001-02-13 | Sankyo Co Ltd | 縮合複素環化合物の塩酸塩 |
WO2001000570A1 (fr) * | 1999-06-28 | 2001-01-04 | Sankyo Company, Limited | Intermediaires pour la synthese de composes de benzimidazole et procede de preparation |
JP2001072671A (ja) | 1999-06-28 | 2001-03-21 | Sankyo Co Ltd | ベンズイミダゾール化合物の合成中間体およびその製造方法 |
JP2001097954A (ja) * | 1999-07-29 | 2001-04-10 | Sankyo Co Ltd | スルホキシベンズイミダゾール誘導体 |
Non-Patent Citations (3)
Title |
---|
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 235 - 238 |
JOURNAL OF CHEMICAL SOCIETY PERKIN TRANSACTIONS I, 1992, pages 973 - 978 |
See also references of EP1894929A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10064850B2 (en) | 2007-04-11 | 2018-09-04 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
Also Published As
Publication number | Publication date |
---|---|
TW200637856A (en) | 2006-11-01 |
KR20070098872A (ko) | 2007-10-05 |
EP1894929A4 (en) | 2009-12-30 |
CA2699633A1 (en) | 2006-07-27 |
EP2226321A2 (en) | 2010-09-08 |
EP1894929A1 (en) | 2008-03-05 |
CA2595782C (en) | 2011-01-04 |
BRPI0606931A2 (pt) | 2009-12-01 |
CN101146805A (zh) | 2008-03-19 |
IL184598A0 (en) | 2007-10-31 |
CA2595782A1 (en) | 2006-07-27 |
US20080103185A1 (en) | 2008-05-01 |
EP2226321A3 (en) | 2011-01-26 |
US20110092555A1 (en) | 2011-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022138988A1 (ja) | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 | |
TWI444378B (zh) | 具有β-分泌酶抑制作用之含硫雜環衍生物及其用途 | |
US7638627B2 (en) | Process of preparing imatinib and imatinib prepared thereby | |
US9139570B2 (en) | Solid forms of an antiviral compound | |
US20220356180A1 (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
TWI330639B (en) | Oxazole compound and pharmaceutical composition | |
US11192878B2 (en) | Piperidine-2,6-dione derivative and use thereof | |
JPWO2010101164A1 (ja) | ピリジン誘導体 | |
KR20130046436A (ko) | 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도 | |
US20230322723A1 (en) | Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof | |
KR20170076673A (ko) | Kcnq2∼5 채널 활성화제 | |
WO2014010748A1 (en) | Cyclopropane derivative having bace1 inhibiting activity | |
WO2006078037A1 (ja) | チアゾリジンジオン化合物の製造方法及びその製造中間体 | |
JP2018527331A (ja) | 新規な縮合したピリミジノン及びトリアジノン誘導体、それらの調製方法、並びに抗真菌薬及び/又は抗寄生虫薬としてのそれらの治療での使用 | |
JP6940504B2 (ja) | 置換5,6−ジヒドロ−6−フェニルベンゾ[f]イソキノリン−2−アミンを調製するための方法 | |
US20230271955A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
TW475928B (en) | Antirheumatic agent comprising a benzylidene derivative as an active ingredient | |
WO2007004688A1 (ja) | キサンチンオキシダーゼ阻害剤 | |
JP2008044932A (ja) | チアゾリジンジオン化合物を含有する組成物 | |
EP3134092B1 (en) | Pharmaceutical salts of an orexin receptor antagonist | |
CN107922375A (zh) | 靶向idh2突变的抗肿瘤化合物及其使用方法 | |
JP2006225382A (ja) | チアゾリジンジオン化合物の製造方法及びその製造中間体 | |
WO2021230198A1 (ja) | ジヒドロキノリノン化合物の共結晶 | |
US20230357244A1 (en) | Fxr small-molecule agonist, and preparation method therefor and use thereof | |
JP2023511152A (ja) | 呼吸器合胞体ウイルス阻害剤の合成及び使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2454/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006712274 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 184598 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077016748 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2595782 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11795270 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680009404.0 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006712274 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0606931 Country of ref document: BR Kind code of ref document: A2 |